{ "metadata": { "title": "UroLongevity References, Evidence Notes, and Updates", "book_title": "UroLongevity", "subtitle": "The Physician's Guide to Healthspan and Precision Aging", "author": "David Shusterman, MD", "publisher": "UroLongevity Press", "series": "The Urologist's Guide", "edition_version": "2.1", "edition_name": "First Edition", "evidence_reviewed_through": "2026-08-13", "bibliography_compiled": "2026-08-14", "paperback_isbn": "979-8-90649-022-3", "hardcover_isbn": "979-8-90649-023-0", "ebook_isbn": "979-8-90649-002-5", "canonical_url": "https://UroLongevityPress.com/UroLongevity/references", "reference_count": 158 }, "chapters": [ { "number": 1, "title": "The Body Speaks in Signals" }, { "number": 2, "title": "Not a Steroid, Not a Supplement, Not Snake Oil" }, { "number": 3, "title": "The Regulatory Landscape — August 2026 Evidence Review" }, { "number": 4, "title": "Reading the Evidence in a Hype-Saturated Field" }, { "number": 5, "title": "The Biology of Aging" }, { "number": 6, "title": "Semaglutide: More Than a Weight-Loss Drug" }, { "number": 7, "title": "Tirzepatide: Two Signals, One Powerful Therapy" }, { "number": 8, "title": "Liraglutide" }, { "number": 9, "title": "Tesamorelin" }, { "number": 10, "title": "Elamipretide" }, { "number": 11, "title": "PT-141 (Bremelanotide)" }, { "number": 12, "title": "Sermorelin" }, { "number": 13, "title": "Ipamorelin" }, { "number": 14, "title": "CJC-1295" }, { "number": 15, "title": "MK-677 (Ibutamoren)" }, { "number": 16, "title": "Thymosin Alpha-1" }, { "number": 17, "title": "BPC-157" }, { "number": 18, "title": "TB-500 (Thymosin Beta-4)" }, { "number": 19, "title": "GHK-Cu" }, { "number": 20, "title": "Epitalon" }, { "number": 21, "title": "Retatrutide" }, { "number": 22, "title": "LL-37 and KPV" }, { "number": 23, "title": "MOTS-c" }, { "number": 24, "title": "Orforglipron" }, { "number": 25, "title": "NAD⁺ and Its Precursors" }, { "number": 26, "title": "Rapamycin and the mTOR Pathway" }, { "number": 27, "title": "Senolytics — Clearing Senescent Cells" }, { "number": 28, "title": "Testosterone" }, { "number": 29, "title": "Growth Hormone" }, { "number": 30, "title": "Thyroid Hormone" }, { "number": 31, "title": "Female Reproductive Hormones — Perimenopause and Menopause" }, { "number": 32, "title": "DHEA and Adrenal Steroids" }, { "number": 33, "title": "The Integration Framework" }, { "number": 34, "title": "Exercise" }, { "number": 35, "title": "Sleep" }, { "number": 36, "title": "Nutrition" }, { "number": 37, "title": "Mental Work" }, { "number": 38, "title": "Hair Restoration" }, { "number": 39, "title": "Sexual Wellness" }, { "number": 40, "title": "Skin and Aesthetic Interventions" }, { "number": 41, "title": "Bladder, Pelvic Floor, and Continence Rehabilitation" }, { "number": 42, "title": "The Regulatory and Practice Framework" }, { "number": 43, "title": "Integrated Practice" }, { "number": 44, "title": "Early Intervention and the Minimally Invasive Framework" }, { "number": 45, "title": "The First 90 Days" }, { "number": 46, "title": "Maintenance — The Long-Term Framework" }, { "number": 47, "title": "The Lifespan Framework — Adaptation Across Demographics" }, { "number": 48, "title": "The Future of Comprehensive Practice" }, { "number": 49, "title": "What This Medicine Offers and What It Requires" } ], "references": [ { "reference_id": "ULON-REF-0001", "source_order": 1, "author_or_organization": "Adunsky", "publication_year": "2011", "citation_text": "Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011;53:183-189.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Growth Hormone Axis", "MK-677" ], "chapter_numbers": [ 15 ], "chapter_titles": [ "MK-677 (Ibutamoren)" ] }, { "reference_id": "ULON-REF-0002", "source_order": 2, "author_or_organization": "Al-Dulaimi", "publication_year": "2025", "citation_text": "Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. doi:10.1007/s10522-025-10315-x.", "doi": "10.1007/s10522-025-10315-x", "doi_url": "https://doi.org/10.1007/s10522-025-10315-x", "source_url": "https://doi.org/10.1007/s10522-025-10315-x", "source_type": "Journal article or scholarly source", "subject_tags": [ "Epitalon", "Peptides" ], "chapter_numbers": [ 20 ], "chapter_titles": [ "Epitalon" ] }, { "reference_id": "ULON-REF-0003", "source_order": 3, "author_or_organization": "Araj", "publication_year": "2025", "citation_text": "Araj M, Brzezik M, Mądra-Gackowska K, Szeleszczuk Ł. Epitalon — 25 years of research. Int J Mol Sci 2025.", "doi": "", "doi_url": "", "source_url": "https://www.mdpi.com/1422-0067/26/6/2691", "source_type": "Journal article or scholarly source", "subject_tags": [ "Epitalon", "Peptides" ], "chapter_numbers": [ 20 ], "chapter_titles": [ "Epitalon" ] }, { "reference_id": "ULON-REF-0004", "source_order": 4, "author_or_organization": "Aronne", "publication_year": "2025", "citation_text": "Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "GLP-1 and GIP Therapies", "Semaglutide", "Tirzepatide" ], "chapter_numbers": [ 6, 7 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug", "Tirzepatide: Two Signals, One Powerful Therapy" ] }, { "reference_id": "ULON-REF-0005", "source_order": 5, "author_or_organization": "Badenhorst", "publication_year": "2016", "citation_text": "Badenhorst T, Svirskis D, Wu Z. Pharmaceutical strategies for the topical dermal delivery of peptides/proteins for cosmetic and therapeutic applications. Austin J Pharmacol Ther 2016;4:1083.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GHK-Cu", "Skin and Aesthetic Medicine" ], "chapter_numbers": [ 19, 40 ], "chapter_titles": [ "GHK-Cu", "Skin and Aesthetic Interventions" ] }, { "reference_id": "ULON-REF-0006", "source_order": 6, "author_or_organization": "Barzilai", "publication_year": "2016", "citation_text": "Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23:1060-1065. doi:10.1016/j.cmet.2016.05.011.", "doi": "10.1016/j.cmet.2016.05.011", "doi_url": "https://doi.org/10.1016/j.cmet.2016.05.011", "source_url": "https://doi.org/10.1016/j.cmet.2016.05.011", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 26, 48 ], "chapter_titles": [ "Rapamycin and the mTOR Pathway", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0007", "source_order": 7, "author_or_organization": "Bauer", "publication_year": "2013", "citation_text": "Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013;14:542-559.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Lifestyle Foundations", "Nutrition" ], "chapter_numbers": [ 36 ], "chapter_titles": [ "Nutrition" ] }, { "reference_id": "ULON-REF-0008", "source_order": 8, "author_or_organization": "Beck", "publication_year": "2014", "citation_text": "Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29:1527-1534.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Growth Hormone Axis", "Ipamorelin" ], "chapter_numbers": [ 13 ], "chapter_titles": [ "Ipamorelin" ] }, { "reference_id": "ULON-REF-0009", "source_order": 9, "author_or_organization": "Bell", "publication_year": "2019", "citation_text": "Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol 2019;20:249.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Lifespan Framework" ], "chapter_numbers": [ 47 ], "chapter_titles": [ "The Lifespan Framework — Adaptation Across Demographics" ] }, { "reference_id": "ULON-REF-0010", "source_order": 10, "author_or_organization": "Belsky", "publication_year": "2022", "citation_text": "Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife 2022;11:e73420.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Lifespan Framework" ], "chapter_numbers": [ 47, 48 ], "chapter_titles": [ "The Lifespan Framework — Adaptation Across Demographics", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0011", "source_order": 11, "author_or_organization": "Ben-Shlomo", "publication_year": "2020", "citation_text": "Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest 2020;130:5738-5755.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 14 ], "chapter_titles": [ "CJC-1295" ] }, { "reference_id": "ULON-REF-0012", "source_order": 12, "author_or_organization": "Berry", "publication_year": "2020", "citation_text": "Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med 2020;26:964-973.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Lifestyle Foundations", "Nutrition" ], "chapter_numbers": [ 36, 48 ], "chapter_titles": [ "Nutrition", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0013", "source_order": 13, "author_or_organization": "Bjedov", "publication_year": "2010", "citation_text": "Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010;11:35-46.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Rapamycin and mTOR" ], "chapter_numbers": [ 26, 48 ], "chapter_titles": [ "Rapamycin and the mTOR Pathway", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0014", "source_order": 14, "author_or_organization": "Bliss", "publication_year": "1982", "citation_text": "Bliss M. The Discovery of Insulin. University of Chicago Press; 1982.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Book", "subject_tags": [ "Peptide Foundations" ], "chapter_numbers": [ 1, 2 ], "chapter_titles": [ "The Body Speaks in Signals", "Not a Steroid, Not a Supplement, Not Snake Oil" ] }, { "reference_id": "ULON-REF-0015", "source_order": 15, "author_or_organization": "Bock-Marquette", "publication_year": "2004", "citation_text": "Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432:466-472.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Peptides", "TB-500 and Thymosin Beta-4" ], "chapter_numbers": [ 18 ], "chapter_titles": [ "TB-500 (Thymosin Beta-4)" ] }, { "reference_id": "ULON-REF-0016", "source_order": 16, "author_or_organization": "Bornstein", "publication_year": "2016", "citation_text": "Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:364-389.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Guideline or position statement", "subject_tags": [ "DHEA and Adrenal Steroids", "Hormone Optimization" ], "chapter_numbers": [ 32 ], "chapter_titles": [ "DHEA and Adrenal Steroids" ] }, { "reference_id": "ULON-REF-0017", "source_order": 17, "author_or_organization": "Brakedal", "publication_year": "2022", "citation_text": "Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab 2022;34:396-407.e6.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Molecular Longevity", "NAD+" ], "chapter_numbers": [ 25 ], "chapter_titles": [ "NAD⁺ and Its Precursors" ] }, { "reference_id": "ULON-REF-0018", "source_order": 18, "author_or_organization": "Brea-Gómez", "publication_year": "2025", "citation_text": "Brea-Gómez B, Pérez-Llanes R, Ortega-Donaire L, et al. Effectiveness of pelvic floor muscle training with biofeedback in patients undergoing radical prostatectomy: systematic review and meta-analysis. Eur Urol Focus 2025; published online ahead of print.", "doi": "", "doi_url": "", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40318944/", "source_type": "Meta-analysis", "subject_tags": [ "Bladder and Pelvic Floor Health", "Urologic Health" ], "chapter_numbers": [ 41 ], "chapter_titles": [ "Bladder, Pelvic Floor, and Continence Rehabilitation" ] }, { "reference_id": "ULON-REF-0019", "source_order": 19, "author_or_organization": "Bretthauer", "publication_year": "2022", "citation_text": "Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med 2022;387:1547-1556. (NordICC trial.)", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Early Detection and Intervention" ], "chapter_numbers": [ 44 ], "chapter_titles": [ "Early Intervention and the Minimally Invasive Framework" ] }, { "reference_id": "ULON-REF-0020", "source_order": 20, "author_or_organization": "Budoff", "publication_year": "2018", "citation_text": "Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. 2018;39:2401-2408. doi:10.1093/eurheartj/ehy217.", "doi": "10.1093/eurheartj/ehy217", "doi_url": "https://doi.org/10.1093/eurheartj/ehy217", "source_url": "https://doi.org/10.1093/eurheartj/ehy217", "source_type": "Journal article or scholarly source", "subject_tags": [ "Early Detection and Intervention" ], "chapter_numbers": [ 44, 46 ], "chapter_titles": [ "Early Intervention and the Minimally Invasive Framework", "Maintenance — The Long-Term Framework" ] }, { "reference_id": "ULON-REF-0021", "source_order": 21, "author_or_organization": "Cohen", "publication_year": "2019", "citation_text": "Cohen PA, Bass S. Injecting safety into supplements — modernizing the dietary supplement law. N Engl J Med 2019;381:2387-2389.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 23, 35, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "MOTS-c", "Sleep", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0022", "source_order": 22, "author_or_organization": "Corpas", "publication_year": "1992", "citation_text": "Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75:530-535.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 12 ], "chapter_titles": [ "Sermorelin" ] }, { "reference_id": "ULON-REF-0023", "source_order": 23, "author_or_organization": "Cruz-Jentoft", "publication_year": "2019", "citation_text": "Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31. Correction: Age Ageing. 2019;48:601. doi:10.1093/ageing/afy169.", "doi": "10.1093/ageing/afy169", "doi_url": "https://doi.org/10.1093/ageing/afy169", "source_url": "https://doi.org/10.1093/ageing/afy169", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0024", "source_order": 24, "author_or_organization": "Dalmasso", "publication_year": "2008", "citation_text": "Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-178.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "LL-37 and KPV", "Peptides" ], "chapter_numbers": [ 22 ], "chapter_titles": [ "LL-37 and KPV" ] }, { "reference_id": "ULON-REF-0025", "source_order": 25, "author_or_organization": "de Lima Beltrão", "publication_year": "2025", "citation_text": "de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. Treatment Preferences in Patients With Hypothyroidism. J Clin Endocrinol Metab. 2025;110(3):887-900. doi:10.1210/clinem/dgae651.", "doi": "10.1210/clinem/dgae651", "doi_url": "https://doi.org/10.1210/clinem/dgae651", "source_url": "https://doi.org/10.1210/clinem/dgae651", "source_type": "Journal article or scholarly source", "subject_tags": [ "Hormone Optimization", "Thyroid Hormone" ], "chapter_numbers": [ 30 ], "chapter_titles": [ "Thyroid Hormone" ] }, { "reference_id": "ULON-REF-0026", "source_order": 26, "author_or_organization": "United States Congress", "publication_year": "1994", "citation_text": "Dietary Supplement Health and Education Act of 1994, Pub L No. 103-417, 108 Stat 4325 (codified at 21 USC §§ 321 et seq.).", "doi": "", "doi_url": "", "source_url": "", "source_type": "Statute", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0027", "source_order": 27, "author_or_organization": "United States Congress", "publication_year": "2013", "citation_text": "Drug Quality and Security Act, Pub L No. 113-54 (2013).", "doi": "", "doi_url": "", "source_url": "", "source_type": "Statute", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0028", "source_order": 28, "author_or_organization": "Gong", "publication_year": "2019", "citation_text": "Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7:452-461. doi:10.1016/S2213-8587(19)30093-2.", "doi": "10.1016/S2213-8587(19)30093-2", "doi_url": "https://doi.org/10.1016/S2213-8587(19)30093-2", "source_url": "https://doi.org/10.1016/S2213-8587(19)30093-2", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 46 ], "chapter_titles": [ "Maintenance — The Long-Term Framework" ] }, { "reference_id": "ULON-REF-0029", "source_order": 29, "author_or_organization": "Eli Lilly and Company", "publication_year": "2025", "citation_text": "Eli Lilly and Company. Lilly’s retatrutide reduced body weight by 28.7% in adults living with obesity and knee osteoarthritis in pivotal Phase 3 TRIUMPH-4 study. Press release, December 11, 2025.", "doi": "", "doi_url": "", "source_url": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average", "source_type": "Press release or company notice", "subject_tags": [ "GLP-1 and GIP Therapies", "Retatrutide" ], "chapter_numbers": [ 21 ], "chapter_titles": [ "Retatrutide" ] }, { "reference_id": "ULON-REF-0030", "source_order": 30, "author_or_organization": "Endocrine Society", "publication_year": "2026", "citation_text": "Endocrine Society. Testosterone therapy for hypogonadism guideline resources. Clinical practice guideline, current webpage accessed August 13, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy", "source_type": "Guideline or position statement", "subject_tags": [ "Hormone Optimization", "Testosterone" ], "chapter_numbers": [ 28 ], "chapter_titles": [ "Testosterone" ] }, { "reference_id": "ULON-REF-0031", "source_order": 31, "author_or_organization": "Endocrine Society", "publication_year": "2026", "citation_text": "Endocrine Society. Statement on testosterone replacement therapy. July 16, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy", "source_type": "Journal article or scholarly source", "subject_tags": [ "Hormone Optimization", "Testosterone" ], "chapter_numbers": [ 28 ], "chapter_titles": [ "Testosterone" ] }, { "reference_id": "ULON-REF-0032", "source_order": 32, "author_or_organization": "Eng", "publication_year": "1992", "citation_text": "Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-7405.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Peptide Foundations" ], "chapter_numbers": [ 1, 2 ], "chapter_titles": [ "The Body Speaks in Signals", "Not a Steroid, Not a Supplement, Not Snake Oil" ] }, { "reference_id": "ULON-REF-0033", "source_order": 33, "author_or_organization": "Estruch", "publication_year": "2018", "citation_text": "Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Lifestyle Foundations", "Nutrition" ], "chapter_numbers": [ 36 ], "chapter_titles": [ "Nutrition" ] }, { "reference_id": "ULON-REF-0034", "source_order": 34, "author_or_organization": "Falutz", "publication_year": "2007", "citation_text": "Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-2370.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 9 ], "chapter_titles": [ "Tesamorelin" ] }, { "reference_id": "ULON-REF-0035", "source_order": 35, "author_or_organization": "Falutz", "publication_year": "2010", "citation_text": "Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95:4291-4304.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Clinical trial or trial report", "subject_tags": [ "Growth Hormone Axis", "Tesamorelin" ], "chapter_numbers": [ 9 ], "chapter_titles": [ "Tesamorelin" ] }, { "reference_id": "ULON-REF-0036", "source_order": 36, "author_or_organization": "Falutz", "publication_year": "2010", "citation_text": "Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010;53:311-322.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Growth Hormone Axis", "Tesamorelin" ], "chapter_numbers": [ 9 ], "chapter_titles": [ "Tesamorelin" ] }, { "reference_id": "ULON-REF-0037", "source_order": 37, "author_or_organization": "Food and Drug Administration", "publication_year": "2019", "citation_text": "Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes (Rybelsus). News release, September 20, 2019.", "doi": "", "doi_url": "", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf", "source_type": "Government or regulatory source", "subject_tags": [ "GLP-1 Therapies", "Orforglipron" ], "chapter_numbers": [ 24 ], "chapter_titles": [ "Orforglipron" ] }, { "reference_id": "ULON-REF-0038", "source_order": 38, "author_or_organization": "Food and Drug Administration", "publication_year": "2026", "citation_text": "Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act: nomination categories and interim enforcement policy. Current agency webpage, accessed August 13, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act", "source_type": "Government or regulatory source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0039", "source_order": 39, "author_or_organization": "Food and Drug Administration", "publication_year": "2026", "citation_text": "Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. Current agency webpage, accessed August 13, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "source_type": "Government or regulatory source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0040", "source_order": 40, "author_or_organization": "Food and Drug Administration", "publication_year": "2026", "citation_text": "Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated through May 31, 2026; accessed August 13, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "source_type": "Government or regulatory source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0041", "source_order": 41, "author_or_organization": "Food and Drug Administration", "publication_year": "2026", "citation_text": "Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials, including FDA introductory and substance-specific briefing documents for BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500. Accessed August 13, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026", "source_type": "Government or regulatory source", "subject_tags": [ "BPC-157", "Epitalon", "LL-37 and KPV", "MOTS-c", "Mitochondrial Health", "Peptides", "Regulatory and Compounding Policy", "TB-500 and Thymosin Beta-4" ], "chapter_numbers": [ 3, 17, 18, 20, 22, 23, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "BPC-157", "TB-500 (Thymosin Beta-4)", "Epitalon", "LL-37 and KPV", "MOTS-c", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0042", "source_order": 42, "author_or_organization": "Food and Drug Administration", "publication_year": "2025", "citation_text": "Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug safety communication, February 28, 2025.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products", "source_type": "Government or regulatory source", "subject_tags": [ "Hormone Optimization", "Testosterone" ], "chapter_numbers": [ 28 ], "chapter_titles": [ "Testosterone" ] }, { "reference_id": "ULON-REF-0043", "source_order": 43, "author_or_organization": "Food and Drug Administration", "publication_year": "2026", "citation_text": "Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (Lipfendra). News release, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol", "source_type": "Government or regulatory source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0044", "source_order": 44, "author_or_organization": "Food and Drug Administration", "publication_year": "2025", "citation_text": "Food and Drug Administration. FDA approves treatment for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. News release, 2025; ongoing accelerated-approval confirmatory study status accessed August 13, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf", "source_type": "Government or regulatory source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0045", "source_order": 45, "author_or_organization": "Food and Drug Administration", "publication_year": "2025", "citation_text": "Food and Drug Administration. Drug Trials Snapshot: Forzinity (elamipretide). September 2025; accelerated-approval confirmatory study status accessed August 13, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity", "source_type": "Government or regulatory source", "subject_tags": [ "Elamipretide", "Mitochondrial Health" ], "chapter_numbers": [ 10 ], "chapter_titles": [ "Elamipretide" ] }, { "reference_id": "ULON-REF-0046", "source_order": 46, "author_or_organization": "Food and Drug Administration", "publication_year": "2023", "citation_text": "Food and Drug Administration. Interim category 2 of the 503A Bulks List. Federal Register, September 29, 2023.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "source_type": "Government or regulatory source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0047", "source_order": 47, "author_or_organization": "Food and Drug Administration", "publication_year": "2026", "citation_text": "Food and Drug Administration. Removal of certain bulk drug substances from interim category 2 of the 503A Bulks List. Federal Register, April 15, 2026.", "doi": "", "doi_url": "", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "source_type": "Government or regulatory source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0048", "source_order": 48, "author_or_organization": "Frías", "publication_year": "2021", "citation_text": "Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "GLP-1 and GIP Therapies", "Semaglutide", "Tirzepatide" ], "chapter_numbers": [ 6, 7 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug", "Tirzepatide: Two Signals, One Powerful Therapy" ] }, { "reference_id": "ULON-REF-0049", "source_order": 49, "author_or_organization": "Lindström", "publication_year": "2006", "citation_text": "Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679. doi:10.1016/S0140-6736(06)69701-8.", "doi": "10.1016/S0140-6736(06)69701-8", "doi_url": "https://doi.org/10.1016/S0140-6736(06)69701-8", "source_url": "https://doi.org/10.1016/S0140-6736(06)69701-8", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 46 ], "chapter_titles": [ "Maintenance — The Long-Term Framework" ] }, { "reference_id": "ULON-REF-0050", "source_order": 50, "author_or_organization": "Gelbard", "publication_year": "2013", "citation_text": "Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Sexual Wellness", "Urologic Health" ], "chapter_numbers": [ 39 ], "chapter_titles": [ "Sexual Wellness" ] }, { "reference_id": "ULON-REF-0051", "source_order": 51, "author_or_organization": "Goldstein", "publication_year": "1977", "citation_text": "Goldstein AL, Low TLK, McAdoo M, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A 1977;74:725-729.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Immune Health", "Thymosin Alpha-1" ], "chapter_numbers": [ 16, 18 ], "chapter_titles": [ "Thymosin Alpha-1", "TB-500 (Thymosin Beta-4)" ] }, { "reference_id": "ULON-REF-0052", "source_order": 52, "author_or_organization": "Grönberg", "publication_year": "2014", "citation_text": "Grönberg A, Mahlapuu M, Ståhle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014;22:613-621.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "LL-37 and KPV", "Peptides" ], "chapter_numbers": [ 22 ], "chapter_titles": [ "LL-37 and KPV" ] }, { "reference_id": "ULON-REF-0053", "source_order": 53, "author_or_organization": "Gupta", "publication_year": "2022", "citation_text": "Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. J Dermatolog Treat 2022;33:62-72.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Systematic review", "subject_tags": [ "Aesthetic Medicine", "Evidence Evaluation", "Hair Restoration" ], "chapter_numbers": [ 4, 38 ], "chapter_titles": [ "Reading the Evidence in a Hype-Saturated Field", "Hair Restoration" ] }, { "reference_id": "ULON-REF-0054", "source_order": 54, "author_or_organization": "Hannum", "publication_year": "2013", "citation_text": "Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell 2013;49:359-367.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 48 ], "chapter_titles": [ "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0055", "source_order": 55, "author_or_organization": "Harman", "publication_year": "1956", "citation_text": "Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0056", "source_order": 56, "author_or_organization": "Harrison", "publication_year": "2009", "citation_text": "Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392-395.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Rapamycin and mTOR" ], "chapter_numbers": [ 26, 48 ], "chapter_titles": [ "Rapamycin and the mTOR Pathway", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0057", "source_order": 57, "author_or_organization": "Hickson", "publication_year": "2019", "citation_text": "Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 2019;47:446-456.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Senolytics" ], "chapter_numbers": [ 27 ], "chapter_titles": [ "Senolytics — Clearing Senescent Cells" ] }, { "reference_id": "ULON-REF-0058", "source_order": 58, "author_or_organization": "HLB Therapeutics", "publication_year": "2025", "citation_text": "HLB Therapeutics. European Phase 3 SEER-3 topline results for RGN-259 in neurotrophic keratopathy. Company notice, June 24, 2025; independent coverage published July 1, 2025.", "doi": "", "doi_url": "", "source_url": "https://filecache.investorroom.com/mr5ir_regenerx_ir/215/Letter%20to%20Stockholders%206-24-2025.pdf", "source_type": "Press release or company notice", "subject_tags": [ "Peptides", "TB-500 and Thymosin Beta-4" ], "chapter_numbers": [ 18 ], "chapter_titles": [ "TB-500 (Thymosin Beta-4)" ] }, { "reference_id": "ULON-REF-0059", "source_order": 59, "author_or_organization": "Hohl", "publication_year": "2025", "citation_text": "Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093. doi:10.20945/2359-4292-2025-0093.", "doi": "10.20945/2359-4292-2025-0093", "doi_url": "https://doi.org/10.20945/2359-4292-2025-0093", "source_url": "https://doi.org/10.20945/2359-4292-2025-0093", "source_type": "Meta-analysis", "subject_tags": [ "Hormone Optimization", "Testosterone" ], "chapter_numbers": [ 28 ], "chapter_titles": [ "Testosterone" ] }, { "reference_id": "ULON-REF-0060", "source_order": 60, "author_or_organization": "Hohl", "publication_year": "2025", "citation_text": "Hohl A, Marques P, Ronsoni MF, et al. Selective estrogen receptor modulators (SERMs) for male hypogonadism: a meta-analysis of randomized controlled trials. Arch Endocrinol Metab 2025; published online ahead of print.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Meta-analysis", "subject_tags": [ "Hormone Optimization", "Testosterone" ], "chapter_numbers": [ 28 ], "chapter_titles": [ "Testosterone" ] }, { "reference_id": "ULON-REF-0061", "source_order": 61, "author_or_organization": "Horvath", "publication_year": "2018", "citation_text": "Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet 2018;19:371-384.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Lifespan Framework" ], "chapter_numbers": [ 47, 48 ], "chapter_titles": [ "The Lifespan Framework — Adaptation Across Demographics", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0062", "source_order": 62, "author_or_organization": "Horvath", "publication_year": "2013", "citation_text": "Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013;14:R115.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Lifespan Framework" ], "chapter_numbers": [ 47, 48 ], "chapter_titles": [ "The Lifespan Framework — Adaptation Across Demographics", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0063", "source_order": 63, "author_or_organization": "Hróbjartsson", "publication_year": "2012", "citation_text": "Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Systematic review", "subject_tags": [ "Evidence Evaluation" ], "chapter_numbers": [ 4 ], "chapter_titles": [ "Reading the Evidence in a Hype-Saturated Field" ] }, { "reference_id": "ULON-REF-0064", "source_order": 64, "author_or_organization": "Hughes", "publication_year": "2013", "citation_text": "Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med 2013;158:781-790.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Skin and Aesthetic Medicine" ], "chapter_numbers": [ 40 ], "chapter_titles": [ "Skin and Aesthetic Interventions" ] }, { "reference_id": "ULON-REF-0065", "source_order": 65, "author_or_organization": "Imperiale", "publication_year": "2014", "citation_text": "Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-1297. (Cologuard pivotal trial.)", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Early Detection and Intervention" ], "chapter_numbers": [ 44 ], "chapter_titles": [ "Early Intervention and the Minimally Invasive Framework" ] }, { "reference_id": "ULON-REF-0066", "source_order": 66, "author_or_organization": "Ionescu", "publication_year": "2006", "citation_text": "Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792-4797.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "CJC-1295", "Growth Hormone", "Growth Hormone Axis", "Hormone Optimization" ], "chapter_numbers": [ 14, 29 ], "chapter_titles": [ "CJC-1295", "Growth Hormone" ] }, { "reference_id": "ULON-REF-0067", "source_order": 67, "author_or_organization": "Jastreboff", "publication_year": "2022", "citation_text": "Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-216.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 and GIP Therapies", "Tirzepatide" ], "chapter_numbers": [ 7, 21 ], "chapter_titles": [ "Tirzepatide: Two Signals, One Powerful Therapy", "Retatrutide" ] }, { "reference_id": "ULON-REF-0068", "source_order": 68, "author_or_organization": "Jastreboff", "publication_year": "2023", "citation_text": "Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med 2023;389:514-526.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Clinical trial or trial report", "subject_tags": [ "GLP-1 and GIP Therapies", "Retatrutide" ], "chapter_numbers": [ 21 ], "chapter_titles": [ "Retatrutide" ] }, { "reference_id": "ULON-REF-0069", "source_order": 69, "author_or_organization": "Kaeberlein", "publication_year": "2023", "citation_text": "Kaeberlein TL, Green AS, Haddad G, et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience 2023;45:2757-2768.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Rapamycin and mTOR", "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 26, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "Rapamycin and the mTOR Pathway", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0070", "source_order": 70, "author_or_organization": "Kawai", "publication_year": "2020", "citation_text": "Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A 2020;117:29959-29967.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Orforglipron" ], "chapter_numbers": [ 24 ], "chapter_titles": [ "Orforglipron" ] }, { "reference_id": "ULON-REF-0071", "source_order": 71, "author_or_organization": "Khavinson", "publication_year": "2003", "citation_text": "Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-592.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Epitalon", "Peptides" ], "chapter_numbers": [ 3, 19, 20 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "GHK-Cu", "Epitalon" ] }, { "reference_id": "ULON-REF-0072", "source_order": 72, "author_or_organization": "Khavinson", "publication_year": "2003", "citation_text": "Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters 2003;24:233-240.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 3, 19, 20 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "GHK-Cu", "Epitalon" ] }, { "reference_id": "ULON-REF-0073", "source_order": 73, "author_or_organization": "Khorram", "publication_year": "1997", "citation_text": "Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-1479.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 12 ], "chapter_titles": [ "Sermorelin" ] }, { "reference_id": "ULON-REF-0074", "source_order": 74, "author_or_organization": "Kingsberg", "publication_year": "2019", "citation_text": "Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899-908. (RECONNECT-1 and RECONNECT-2.)", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Bremelanotide", "Sexual Wellness", "Urologic Health" ], "chapter_numbers": [ 11, 39 ], "chapter_titles": [ "PT-141 (Bremelanotide)", "Sexual Wellness" ] }, { "reference_id": "ULON-REF-0075", "source_order": 75, "author_or_organization": "Klier", "publication_year": "2025", "citation_text": "Klier S, Dananberg J, Masaki L, et al. Safety and efficacy of senolytic UBX1325 in diabetic macular edema. NEJM Evidence 2025;4:EVIDoa2400009.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Senolytics" ], "chapter_numbers": [ 27 ], "chapter_titles": [ "Senolytics — Clearing Senescent Cells" ] }, { "reference_id": "ULON-REF-0076", "source_order": 76, "author_or_organization": "Kligman", "publication_year": "1986", "citation_text": "Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol 1986;15:836-859.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Skin and Aesthetic Medicine" ], "chapter_numbers": [ 40 ], "chapter_titles": [ "Skin and Aesthetic Interventions" ] }, { "reference_id": "ULON-REF-0077", "source_order": 77, "author_or_organization": "Kokkinos", "publication_year": "2022", "citation_text": "Kokkinos P, Faselis C, Samuel IBH, et al. Cardiorespiratory fitness and mortality risk across the spectra of age, race, and sex. J Am Coll Cardiol 2022;80:598-609.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Exercise", "Lifestyle Foundations" ], "chapter_numbers": [ 33, 34 ], "chapter_titles": [ "The Integration Framework", "Exercise" ] }, { "reference_id": "ULON-REF-0078", "source_order": 78, "author_or_organization": "Kosiborod", "publication_year": "2023", "citation_text": "Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-1084.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Semaglutide" ], "chapter_numbers": [ 6 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug" ] }, { "reference_id": "ULON-REF-0079", "source_order": 79, "author_or_organization": "Lee", "publication_year": "2015", "citation_text": "Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443-454.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "MOTS-c", "Mitochondrial Health" ], "chapter_numbers": [ 23 ], "chapter_titles": [ "MOTS-c" ] }, { "reference_id": "ULON-REF-0080", "source_order": 80, "author_or_organization": "Lehallier", "publication_year": "2019", "citation_text": "Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 2019;25:1843-1850.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Lifespan Framework" ], "chapter_numbers": [ 47, 48 ], "chapter_titles": [ "The Lifespan Framework — Adaptation Across Demographics", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0081", "source_order": 81, "author_or_organization": "Leong", "publication_year": "2015", "citation_text": "Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015;386:266-273.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Exercise", "Lifestyle Foundations" ], "chapter_numbers": [ 34, 43, 45, 46 ], "chapter_titles": [ "Exercise", "Integrated Practice", "The First 90 Days", "Maintenance — The Long-Term Framework" ] }, { "reference_id": "ULON-REF-0082", "source_order": 82, "author_or_organization": "Levine", "publication_year": "2018", "citation_text": "Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY) 2018;10:573-591. (PhenoAge.)", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Lifespan Framework" ], "chapter_numbers": [ 47, 48 ], "chapter_titles": [ "The Lifespan Framework — Adaptation Across Demographics", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0083", "source_order": 83, "author_or_organization": "Lincoff", "publication_year": "2023", "citation_text": "Lincoff AM, Bhasin S, Flevaris P, et al; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023;389:107-117.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Hormone Optimization", "Testosterone" ], "chapter_numbers": [ 28 ], "chapter_titles": [ "Testosterone" ] }, { "reference_id": "ULON-REF-0084", "source_order": 84, "author_or_organization": "Lincoff", "publication_year": "2023", "citation_text": "Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-2232.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Semaglutide" ], "chapter_numbers": [ 6, 28 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug", "Testosterone" ] }, { "reference_id": "ULON-REF-0085", "source_order": 85, "author_or_organization": "Liu", "publication_year": "2007", "citation_text": "Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-115.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Systematic review", "subject_tags": [ "Growth Hormone", "Hormone Optimization" ], "chapter_numbers": [ 29 ], "chapter_titles": [ "Growth Hormone" ] }, { "reference_id": "ULON-REF-0086", "source_order": 86, "author_or_organization": "Livingston", "publication_year": "2020", "citation_text": "Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413-446.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Cognitive Health", "Mental Work" ], "chapter_numbers": [ 37, 47 ], "chapter_titles": [ "Mental Work", "The Lifespan Framework — Adaptation Across Demographics" ] }, { "reference_id": "ULON-REF-0087", "source_order": 87, "author_or_organization": "Low", "publication_year": "1981", "citation_text": "Low TLK, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A 1981;78:1162-1166.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Peptides", "TB-500 and Thymosin Beta-4" ], "chapter_numbers": [ 18 ], "chapter_titles": [ "TB-500 (Thymosin Beta-4)" ] }, { "reference_id": "ULON-REF-0088", "source_order": 88, "author_or_organization": "Lu", "publication_year": "2019", "citation_text": "Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY) 2019;11:303-327.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Lifespan Framework" ], "chapter_numbers": [ 47 ], "chapter_titles": [ "The Lifespan Framework — Adaptation Across Demographics" ] }, { "reference_id": "ULON-REF-0089", "source_order": 89, "author_or_organization": "Lucente", "publication_year": "2024", "citation_text": "Lucente V, MacDiarmid S, Khera M, et al. Two-year results from a prospective, multicenter, single-arm pivotal study of an implantable tibial neuromodulation system for the treatment of urinary urgency incontinence. Urology 2024;186:80-87.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Bladder and Pelvic Floor Health", "Urologic Health" ], "chapter_numbers": [ 41 ], "chapter_titles": [ "Bladder, Pelvic Floor, and Continence Rehabilitation" ] }, { "reference_id": "ULON-REF-0090", "source_order": 90, "author_or_organization": "Lundh", "publication_year": "2017", "citation_text": "Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Evidence Evaluation" ], "chapter_numbers": [ 4 ], "chapter_titles": [ "Reading the Evidence in a Hype-Saturated Field" ] }, { "reference_id": "ULON-REF-0091", "source_order": 91, "author_or_organization": "López-Otín", "publication_year": "2023", "citation_text": "López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell 2023;186:243-278.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biology of Aging", "Future of Longevity Medicine" ], "chapter_numbers": [ 5, 48 ], "chapter_titles": [ "The Biology of Aging", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0092", "source_order": 92, "author_or_organization": "López-Otín", "publication_year": "2013", "citation_text": "López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-1217.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biology of Aging", "Future of Longevity Medicine" ], "chapter_numbers": [ 5, 48 ], "chapter_titles": [ "The Biology of Aging", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0093", "source_order": 93, "author_or_organization": "Malhotra", "publication_year": "2024", "citation_text": "Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193-1205.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 and GIP Therapies", "Lifestyle Foundations", "Sleep", "Tirzepatide" ], "chapter_numbers": [ 7, 35 ], "chapter_titles": [ "Tirzepatide: Two Signals, One Powerful Therapy", "Sleep" ] }, { "reference_id": "ULON-REF-0094", "source_order": 94, "author_or_organization": "Mandsager", "publication_year": "2018", "citation_text": "Mandsager K, Harb S, Cremer P, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 2018;1:e183605.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Exercise", "Lifestyle Foundations" ], "chapter_numbers": [ 33, 34, 43 ], "chapter_titles": [ "The Integration Framework", "Exercise", "Integrated Practice" ] }, { "reference_id": "ULON-REF-0095", "source_order": 95, "author_or_organization": "Mannick", "publication_year": "2014", "citation_text": "Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014;6:268ra179.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Rapamycin and mTOR" ], "chapter_numbers": [ 26, 48 ], "chapter_titles": [ "Rapamycin and the mTOR Pathway", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0096", "source_order": 96, "author_or_organization": "Mannick", "publication_year": "2018", "citation_text": "Mannick JB, Morris M, Hockey HU, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018;10:eaaq1564.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Rapamycin and mTOR" ], "chapter_numbers": [ 26, 48 ], "chapter_titles": [ "Rapamycin and the mTOR Pathway", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0097", "source_order": 97, "author_or_organization": "Manson", "publication_year": "2013", "citation_text": "Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Female Reproductive Hormones", "Hormone Optimization" ], "chapter_numbers": [ 31 ], "chapter_titles": [ "Female Reproductive Hormones — Perimenopause and Menopause" ] }, { "reference_id": "ULON-REF-0098", "source_order": 98, "author_or_organization": "Marso", "publication_year": "2016", "citation_text": "Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Semaglutide" ], "chapter_numbers": [ 6 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug" ] }, { "reference_id": "ULON-REF-0099", "source_order": 99, "author_or_organization": "Marso", "publication_year": "2016", "citation_text": "Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Liraglutide" ], "chapter_numbers": [ 8 ], "chapter_titles": [ "Liraglutide" ] }, { "reference_id": "ULON-REF-0100", "source_order": 100, "author_or_organization": "Martens", "publication_year": "2018", "citation_text": "Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. Nat Commun 2018;9:1286.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "NAD+" ], "chapter_numbers": [ 25 ], "chapter_titles": [ "NAD⁺ and Its Precursors" ] }, { "reference_id": "ULON-REF-0101", "source_order": 101, "author_or_organization": "McDermott", "publication_year": "2024", "citation_text": "McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun 2024;15:5046.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Molecular Longevity", "NAD+" ], "chapter_numbers": [ 25 ], "chapter_titles": [ "NAD⁺ and Its Precursors" ] }, { "reference_id": "ULON-REF-0102", "source_order": 102, "author_or_organization": "McEvoy", "publication_year": "2016", "citation_text": "McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919-931.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Lifestyle Foundations", "Sleep" ], "chapter_numbers": [ 35 ], "chapter_titles": [ "Sleep" ] }, { "reference_id": "ULON-REF-0103", "source_order": 103, "author_or_organization": "Merrifield", "publication_year": "1963", "citation_text": "Merrifield RB. Solid phase peptide synthesis I: The synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149-2154. (Nobel Prize in Chemistry, 1984.)", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Peptide Foundations" ], "chapter_numbers": [ 1, 2 ], "chapter_titles": [ "The Body Speaks in Signals", "Not a Steroid, Not a Supplement, Not Snake Oil" ] }, { "reference_id": "ULON-REF-0104", "source_order": 104, "author_or_organization": "MESA Investigators", "publication_year": "", "citation_text": "MESA Investigators — see Budoff MJ et al. (above) for the contemporary CAC-mortality framework citation.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Cross-reference", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0105", "source_order": 105, "author_or_organization": "Moel", "publication_year": "2025", "citation_text": "Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025;17:908-936.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Rapamycin and mTOR" ], "chapter_numbers": [ 26, 48 ], "chapter_titles": [ "Rapamycin and the mTOR Pathway", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0106", "source_order": 106, "author_or_organization": "Nadon", "publication_year": "2017", "citation_text": "Nadon NL, Strong R, Miller RA, Harrison DE. NIA Interventions Testing Program: investigating putative aging intervention agents in a genetically heterogeneous mouse model. eBioMedicine 2017;21:3-4.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0107", "source_order": 107, "author_or_organization": "Nair", "publication_year": "2006", "citation_text": "Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647-1659.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "DHEA and Adrenal Steroids", "Hormone Optimization", "Testosterone" ], "chapter_numbers": [ 28, 32 ], "chapter_titles": [ "Testosterone", "DHEA and Adrenal Steroids" ] }, { "reference_id": "ULON-REF-0108", "source_order": 108, "author_or_organization": "Nass", "publication_year": "2008", "citation_text": "Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-611.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [], "chapter_numbers": [ 15 ], "chapter_titles": [ "MK-677 (Ibutamoren)" ] }, { "reference_id": "ULON-REF-0109", "source_order": 109, "author_or_organization": "Ngandu", "publication_year": "2015", "citation_text": "Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255-2263.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Cognitive Health", "Lifestyle Foundations", "Mental Work", "Nutrition" ], "chapter_numbers": [ 36, 37, 43 ], "chapter_titles": [ "Nutrition", "Mental Work", "Integrated Practice" ] }, { "reference_id": "ULON-REF-0110", "source_order": 110, "author_or_organization": "Nicholls", "publication_year": "2025", "citation_text": "Nicholls SJ, Bhatt DL, Buse JB, et al; SURPASS-CVOT Investigators. Cardiovascular efficacy and safety of tirzepatide in patients with type 2 diabetes and atherosclerotic cardiovascular disease. N Engl J Med 2025;393:2347-2358.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 and GIP Therapies", "Tirzepatide" ], "chapter_numbers": [ 7 ], "chapter_titles": [ "Tirzepatide: Two Signals, One Powerful Therapy" ] }, { "reference_id": "ULON-REF-0111", "source_order": 111, "author_or_organization": "Nishihara", "publication_year": "2013", "citation_text": "Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 44, 46 ], "chapter_titles": [ "Early Intervention and the Minimally Invasive Framework", "Maintenance — The Long-Term Framework" ] }, { "reference_id": "ULON-REF-0112", "source_order": 112, "author_or_organization": "Nobel Assembly at Karolinska Institutet", "publication_year": "2009", "citation_text": "Nobel Assembly at Karolinska Institutet. The Nobel Prize in Physiology or Medicine 2009: Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak. October 5, 2009.", "doi": "", "doi_url": "", "source_url": "https://www.nobelprize.org/prizes/medicine/2009/press-release/", "source_type": "Institutional historical source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0113", "source_order": 113, "author_or_organization": "Novo Nordisk", "publication_year": "2025", "citation_text": "Novo Nordisk. Evoke and evoke+ trials of oral semaglutide in early Alzheimer’s disease did not meet primary endpoint. Press release, November 24, 2025.", "doi": "", "doi_url": "", "source_url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462", "source_type": "Press release or company notice", "subject_tags": [ "Cognitive Health", "GLP-1 Therapies", "Mental Work", "Semaglutide" ], "chapter_numbers": [ 6, 37 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug", "Mental Work" ] }, { "reference_id": "ULON-REF-0114", "source_order": 114, "author_or_organization": "Ocampo", "publication_year": "2016", "citation_text": "Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 2016;167:1719-1733.e12.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biology of Aging", "Future of Longevity Medicine" ], "chapter_numbers": [ 5, 48 ], "chapter_titles": [ "The Biology of Aging", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0115", "source_order": 115, "author_or_organization": "Outterson", "publication_year": "2012", "citation_text": "Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med 2012;367:1969-1972.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0116", "source_order": 116, "author_or_organization": "Appel", "publication_year": "2003", "citation_text": "Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093. doi:10.1001/jama.289.16.2083.", "doi": "10.1001/jama.289.16.2083", "doi_url": "https://doi.org/10.1001/jama.289.16.2083", "source_url": "https://doi.org/10.1001/jama.289.16.2083", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0117", "source_order": 117, "author_or_organization": "Mack", "publication_year": "2019", "citation_text": "Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. doi:10.1056/NEJMoa1814052.", "doi": "10.1056/NEJMoa1814052", "doi_url": "https://doi.org/10.1056/NEJMoa1814052", "source_url": "https://doi.org/10.1056/NEJMoa1814052", "source_type": "Journal article or scholarly source", "subject_tags": [ "Early Detection and Intervention" ], "chapter_numbers": [ 44 ], "chapter_titles": [ "Early Intervention and the Minimally Invasive Framework" ] }, { "reference_id": "ULON-REF-0118", "source_order": 118, "author_or_organization": "Patchett", "publication_year": "1995", "citation_text": "Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A 1995;92:7001-7005.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Growth Hormone Axis", "MK-677" ], "chapter_numbers": [ 15 ], "chapter_titles": [ "MK-677 (Ibutamoren)" ] }, { "reference_id": "ULON-REF-0119", "source_order": 119, "author_or_organization": "Paulescu", "publication_year": "1921", "citation_text": "Paulescu NC. Recherche sur le rôle du pancréas dans l’assimilation nutritive. Arch Int Physiol 1921;17:85-103.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [], "chapter_titles": [] }, { "reference_id": "ULON-REF-0120", "source_order": 120, "author_or_organization": "Penha", "publication_year": "2024", "citation_text": "Penha MÁ, Miot HA, Kasprzak M, et al. Oral minoxidil 5 mg daily versus topical minoxidil 5% twice daily for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol 2024;160:600-605.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Aesthetic Medicine", "Hair Restoration" ], "chapter_numbers": [ 38 ], "chapter_titles": [ "Hair Restoration" ] }, { "reference_id": "ULON-REF-0121", "source_order": 121, "author_or_organization": "Peppard", "publication_year": "2013", "citation_text": "Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177:1006-1014.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Lifestyle Foundations", "Sleep" ], "chapter_numbers": [ 35 ], "chapter_titles": [ "Sleep" ] }, { "reference_id": "ULON-REF-0122", "source_order": 122, "author_or_organization": "Perkovic", "publication_year": "2024", "citation_text": "Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109-121.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Semaglutide" ], "chapter_numbers": [ 6 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug" ] }, { "reference_id": "ULON-REF-0123", "source_order": 123, "author_or_organization": "Perls", "publication_year": "2005", "citation_text": "Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. JAMA 2005;294:2086-2090.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Growth Hormone", "Hormone Optimization" ], "chapter_numbers": [ 29 ], "chapter_titles": [ "Growth Hormone" ] }, { "reference_id": "ULON-REF-0124", "source_order": 124, "author_or_organization": "Peters", "publication_year": "2010", "citation_text": "Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010;183:1438-1443.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Bladder and Pelvic Floor Health", "Urologic Health" ], "chapter_numbers": [ 41 ], "chapter_titles": [ "Bladder, Pelvic Floor, and Continence Rehabilitation" ] }, { "reference_id": "ULON-REF-0125", "source_order": 125, "author_or_organization": "Pi-Sunyer", "publication_year": "2015", "citation_text": "Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "GLP-1 Therapies", "Liraglutide" ], "chapter_numbers": [ 8 ], "chapter_titles": [ "Liraglutide" ] }, { "reference_id": "ULON-REF-0126", "source_order": 126, "author_or_organization": "Pickart", "publication_year": "1980", "citation_text": "Pickart L, Thaler MM. Growth-modulating tripeptide (glycyl-histidyl-lysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol 1980;102:129-139.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GHK-Cu", "Skin and Aesthetic Medicine" ], "chapter_numbers": [ 19, 40 ], "chapter_titles": [ "GHK-Cu", "Skin and Aesthetic Interventions" ] }, { "reference_id": "ULON-REF-0127", "source_order": 127, "author_or_organization": "Pickart", "publication_year": "2015", "citation_text": "Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GHK-Cu", "Skin and Aesthetic Medicine" ], "chapter_numbers": [ 19, 40 ], "chapter_titles": [ "GHK-Cu", "Skin and Aesthetic Interventions" ] }, { "reference_id": "ULON-REF-0128", "source_order": 128, "author_or_organization": "Radley", "publication_year": "2006", "citation_text": "Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0129", "source_order": 129, "author_or_organization": "Raun", "publication_year": "1998", "citation_text": "Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552-561.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Growth Hormone Axis", "Ipamorelin" ], "chapter_numbers": [ 13 ], "chapter_titles": [ "Ipamorelin" ] }, { "reference_id": "ULON-REF-0130", "source_order": 130, "author_or_organization": "Reid Thompson", "publication_year": "2021", "citation_text": "Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med 2021;23:471-478. (TAZPOWER trial.)", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Elamipretide", "Mitochondrial Health" ], "chapter_numbers": [ 10 ], "chapter_titles": [ "Elamipretide" ] }, { "reference_id": "ULON-REF-0131", "source_order": 131, "author_or_organization": "Reynolds", "publication_year": "2021", "citation_text": "Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021;12:470.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Exercise", "Lifestyle Foundations", "MOTS-c", "Mitochondrial Health" ], "chapter_numbers": [ 23, 34 ], "chapter_titles": [ "MOTS-c", "Exercise" ] }, { "reference_id": "ULON-REF-0132", "source_order": 132, "author_or_organization": "Romani", "publication_year": "2004", "citation_text": "Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-4239.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Immune Health", "Thymosin Alpha-1" ], "chapter_numbers": [ 16 ], "chapter_titles": [ "Thymosin Alpha-1" ] }, { "reference_id": "ULON-REF-0133", "source_order": 133, "author_or_organization": "Safarinejad", "publication_year": "2008", "citation_text": "Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179:1066-1071.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Bremelanotide", "Sexual Wellness", "Urologic Health" ], "chapter_numbers": [ 11, 39 ], "chapter_titles": [ "PT-141 (Bremelanotide)", "Sexual Wellness" ] }, { "reference_id": "ULON-REF-0134", "source_order": 134, "author_or_organization": "Sanyal", "publication_year": "2025", "citation_text": "Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089-2099.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Clinical trial or trial report", "subject_tags": [ "GLP-1 Therapies", "Semaglutide" ], "chapter_numbers": [ 6 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug" ] }, { "reference_id": "ULON-REF-0135", "source_order": 135, "author_or_organization": "Savin", "publication_year": "2024", "citation_text": "Savin MJ, Wang H, Pei H, et al. Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort. Alzheimers Dement (Amst). 2024;16(4):e70038. doi:10.1002/dad2.70038.", "doi": "10.1002/dad2.70038", "doi_url": "https://doi.org/10.1002/dad2.70038", "source_url": "https://doi.org/10.1002/dad2.70038", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biological Aging", "Cognitive Health", "Lifespan Framework", "Mental Work" ], "chapter_numbers": [ 37, 47, 48 ], "chapter_titles": [ "Mental Work", "The Lifespan Framework — Adaptation Across Demographics", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0136", "source_order": 136, "author_or_organization": "Schmauck-Medina", "publication_year": "2022", "citation_text": "Schmauck-Medina T, Molière A, Lautrup S, et al. New hallmarks of ageing: a 2022 Copenhagen ageing meeting summary. Aging (Albany NY) 2022;14:6829-6839.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Biology of Aging", "Future of Longevity Medicine" ], "chapter_numbers": [ 5, 48 ], "chapter_titles": [ "The Biology of Aging", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0137", "source_order": 137, "author_or_organization": "Schweiger", "publication_year": "2025", "citation_text": "Schweiger A, Diniz B, Nicol G, et al. Protocol for a pilot clinical trial of the senolytic drug combination dasatinib plus quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Res. 2025;13:1072. doi:10.12688/f1000research.151963.2.", "doi": "10.12688/f1000research.151963.2", "doi_url": "https://doi.org/10.12688/f1000research.151963.2", "source_url": "https://doi.org/10.12688/f1000research.151963.2", "source_type": "Journal article or scholarly source", "subject_tags": [ "Cognitive Health", "Mental Work", "Molecular Longevity", "Senolytics" ], "chapter_numbers": [ 27, 37, 48 ], "chapter_titles": [ "Senolytics — Clearing Senescent Cells", "Mental Work", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0138", "source_order": 138, "author_or_organization": "Sikiric", "publication_year": "1993", "citation_text": "Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993;87:313-327.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "BPC-157", "Peptides" ], "chapter_numbers": [ 17 ], "chapter_titles": [ "BPC-157" ] }, { "reference_id": "ULON-REF-0139", "source_order": 139, "author_or_organization": "Simon", "publication_year": "2019", "citation_text": "Simon JA, Kingsberg SA, Goldstein I, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134:909-917.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Bremelanotide", "Sexual Wellness", "Urologic Health" ], "chapter_numbers": [ 11, 39 ], "chapter_titles": [ "PT-141 (Bremelanotide)", "Sexual Wellness" ] }, { "reference_id": "ULON-REF-0140", "source_order": 140, "author_or_organization": "Sosne", "publication_year": "2023", "citation_text": "Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci 2023;24:554.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Peptides", "TB-500 and Thymosin Beta-4" ], "chapter_numbers": [ 18 ], "chapter_titles": [ "TB-500 (Thymosin Beta-4)" ] }, { "reference_id": "ULON-REF-0141", "source_order": 141, "author_or_organization": "Stanley", "publication_year": "2019", "citation_text": "Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821-e830.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Randomized clinical trial", "subject_tags": [ "Growth Hormone Axis", "Tesamorelin" ], "chapter_numbers": [ 9 ], "chapter_titles": [ "Tesamorelin" ] }, { "reference_id": "ULON-REF-0142", "source_order": 142, "author_or_organization": "Stealth BioTherapeutics Inc", "publication_year": "2025", "citation_text": "Stealth BioTherapeutics Inc. Stealth BioTherapeutics announces FDA accelerated approval of Forzinity (elamipretide HCl), the first therapy for progressive and life-limiting ultra-rare genetic disease Barth syndrome. Press release, September 19, 2025.", "doi": "", "doi_url": "", "source_url": "https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome/", "source_type": "Press release or company notice", "subject_tags": [ "Elamipretide", "Mitochondrial Health" ], "chapter_numbers": [ 10 ], "chapter_titles": [ "Elamipretide" ] }, { "reference_id": "ULON-REF-0143", "source_order": 143, "author_or_organization": "Stott", "publication_year": "2017", "citation_text": "Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 2017;376:2534-2544. (TRUST trial.)", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Hormone Optimization", "Thyroid Hormone" ], "chapter_numbers": [ 30, 47 ], "chapter_titles": [ "Thyroid Hormone", "The Lifespan Framework — Adaptation Across Demographics" ] }, { "reference_id": "ULON-REF-0144", "source_order": 144, "author_or_organization": "Talpos", "publication_year": "2026", "citation_text": "Talpos S. How a Croatian Lab Spawned a Buzzy Peptide Now Popular With MAHA. Undark. February 3, 2026. Co-published by STAT.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [], "chapter_numbers": [ 17 ], "chapter_titles": [ "BPC-157" ] }, { "reference_id": "ULON-REF-0145", "source_order": 145, "author_or_organization": "Teichman", "publication_year": "2006", "citation_text": "Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91:799-805.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "CJC-1295", "Growth Hormone", "Growth Hormone Axis", "Hormone Optimization" ], "chapter_numbers": [ 14, 29 ], "chapter_titles": [ "CJC-1295", "Growth Hormone" ] }, { "reference_id": "ULON-REF-0146", "source_order": 146, "author_or_organization": "North American Menopause Society Advisory Panel", "publication_year": "2022", "citation_text": "The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause 2022;29:767-794.", "doi": "", "doi_url": "", "source_url": "https://menopause.org/professional-resources/position-statements", "source_type": "Guideline or position statement", "subject_tags": [ "Female Reproductive Hormones", "Hormone Optimization" ], "chapter_numbers": [ 31 ], "chapter_titles": [ "Female Reproductive Hormones — Perimenopause and Menopause" ] }, { "reference_id": "ULON-REF-0147", "source_order": 147, "author_or_organization": "U.S. Department of Justice", "publication_year": "2020", "citation_text": "U.S. Department of Justice. Nicholasville compounding pharmacy and its owner plead guilty to unlawful distribution of prescription drugs. Press release, October 5, 2020. (Tailor Made Compounding LLC.)", "doi": "", "doi_url": "", "source_url": "https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution", "source_type": "Government or regulatory source", "subject_tags": [ "Regulatory and Compounding Policy" ], "chapter_numbers": [ 3, 42 ], "chapter_titles": [ "The Regulatory Landscape — August 2026 Evidence Review", "The Regulatory and Practice Framework" ] }, { "reference_id": "ULON-REF-0148", "source_order": 148, "author_or_organization": "McGuire", "publication_year": "2025", "citation_text": "McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619. doi:10.1007/s12178-025-09990-7.", "doi": "10.1007/s12178-025-09990-7", "doi_url": "https://doi.org/10.1007/s12178-025-09990-7", "source_url": "https://doi.org/10.1007/s12178-025-09990-7", "source_type": "Review article", "subject_tags": [ "BPC-157", "Peptides" ], "chapter_numbers": [ 17 ], "chapter_titles": [ "BPC-157" ] }, { "reference_id": "ULON-REF-0149", "source_order": 149, "author_or_organization": "Vandamme", "publication_year": "2012", "citation_text": "Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012;280:22-35.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "LL-37 and KPV", "Peptides" ], "chapter_numbers": [ 22 ], "chapter_titles": [ "LL-37 and KPV" ] }, { "reference_id": "ULON-REF-0150", "source_order": 150, "author_or_organization": "Vittone", "publication_year": "1997", "citation_text": "Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Growth Hormone", "Hormone Optimization" ], "chapter_numbers": [ 12, 29 ], "chapter_titles": [ "Sermorelin", "Growth Hormone" ] }, { "reference_id": "ULON-REF-0151", "source_order": 151, "author_or_organization": "Wang", "publication_year": "2022", "citation_text": "Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 2022;7:48.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Peptide Foundations" ], "chapter_numbers": [ 1, 2, 46 ], "chapter_titles": [ "The Body Speaks in Signals", "Not a Steroid, Not a Supplement, Not Snake Oil", "Maintenance — The Long-Term Framework" ] }, { "reference_id": "ULON-REF-0152", "source_order": 152, "author_or_organization": "Wharton", "publication_year": "2023", "citation_text": "Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392.", "doi": "10.1056/NEJMoa2302392", "doi_url": "https://doi.org/10.1056/NEJMoa2302392", "source_url": "https://doi.org/10.1056/NEJMoa2302392", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Orforglipron" ], "chapter_numbers": [ 24 ], "chapter_titles": [ "Orforglipron" ] }, { "reference_id": "ULON-REF-0153", "source_order": 153, "author_or_organization": "Wilding", "publication_year": "2021", "citation_text": "Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "GLP-1 Therapies", "Semaglutide" ], "chapter_numbers": [ 6 ], "chapter_titles": [ "Semaglutide: More Than a Weight-Loss Drug" ] }, { "reference_id": "ULON-REF-0154", "source_order": 154, "author_or_organization": "Xu", "publication_year": "2018", "citation_text": "Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med 2018;24:1246-1256.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Exercise", "Lifestyle Foundations", "Molecular Longevity", "Senolytics" ], "chapter_numbers": [ 27, 34 ], "chapter_titles": [ "Senolytics — Clearing Senescent Cells", "Exercise" ] }, { "reference_id": "ULON-REF-0155", "source_order": 155, "author_or_organization": "Zauber", "publication_year": "2012", "citation_text": "Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687-696. doi:10.1056/NEJMoa1100370.", "doi": "10.1056/NEJMoa1100370", "doi_url": "https://doi.org/10.1056/NEJMoa1100370", "source_url": "https://doi.org/10.1056/NEJMoa1100370", "source_type": "Journal article or scholarly source", "subject_tags": [ "Early Detection and Intervention" ], "chapter_numbers": [ 44 ], "chapter_titles": [ "Early Intervention and the Minimally Invasive Framework" ] }, { "reference_id": "ULON-REF-0156", "source_order": 156, "author_or_organization": "Zeevi", "publication_year": "2015", "citation_text": "Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-1094.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Lifestyle Foundations", "Nutrition" ], "chapter_numbers": [ 36, 48 ], "chapter_titles": [ "Nutrition", "The Future of Comprehensive Practice" ] }, { "reference_id": "ULON-REF-0157", "source_order": 157, "author_or_organization": "Zhang", "publication_year": "2009", "citation_text": "Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Meta-analysis", "subject_tags": [ "Immune Health", "Thymosin Alpha-1" ], "chapter_numbers": [ 16, 46 ], "chapter_titles": [ "Thymosin Alpha-1", "Maintenance — The Long-Term Framework" ] }, { "reference_id": "ULON-REF-0158", "source_order": 158, "author_or_organization": "Zhu", "publication_year": "2015", "citation_text": "Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015;14:644-658.", "doi": "", "doi_url": "", "source_url": "", "source_type": "Journal article or scholarly source", "subject_tags": [ "Molecular Longevity", "Senolytics" ], "chapter_numbers": [ 27 ], "chapter_titles": [ "Senolytics — Clearing Senescent Cells" ] } ] }